FDA Grants Marketing Approval For SCENESSE


It is a privilege for CLINUVEL PHARMACEUTICALS LTD to announce the US Food & Drug Administration (FDA) has granted marketing approval to use SCENESSE® (afamelanotide 16mg) for the treatment of EPP patients in the United States.

Download PDF

We use cookies to give you the best experience.